Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.43 |
| ▸ | P2RY10 | O00398 | 5/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.42 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.38 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17504769 | 0.96 | PLA2G2C (0.46) | PLA2G2CP2RY10FOLH1GRM3NAALAD2 | |
| SCHEMBL20214857 | 0.86 | FOLH1 (0.50) | FOLH1GRM3NAALAD2 | |
| SCHEMBL17504771 | 0.80 | PLA2G2C (0.44) | PLA2G2CLPAR3LPAR1LPAR2 | |
| SCHEMBL17504764 | 0.78 | FOLH1 (0.58) | FOLH1GRM3NAALAD2 | |
| SCHEMBL17533765 | 0.76 | FOLH1 (0.54) | FOLH1GRM3NAALAD2 | |
| SCHEMBL2359678 | 0.76 | PLA2G2C (0.61) | PLA2G2C | |
| SCHEMBL8053866 | 0.75 | FOLH1 (0.59) | FOLH1GRM3NAALAD2 | |
| SCHEMBL26424133 | 0.75 | FOLH1 (0.39) | P2RY10FOLH1GRM3NAALAD2GPR34 | |
| SCHEMBL8771201 | 0.74 | GRIK1 (0.53) | PLA2G2C | |
| SCHEMBL11068865 | 0.74 | GRIK1 (0.53) | PLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988407-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170226141-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226141-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | FOLH1, KLK3, DNPEP | PLA2G2C 195/4885P2RY10 881/4885FOLH1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.